Her suggestion could possibly lessen the burden on the government, which is grappling to get a measure of the exact cost to vaccinate the entire country and getting the logistics and supply chain in place to administer the vaccine. It is estimated that it could cost a minimum of Rs 50,000 crore to vaccinate the country.

Focus on growth, investments; capacity in Biologics a growth driver: Syngene Intl

EBITDA Margins around 31-33% with focus on growth and investments are good, said Jonathan Hunt, CEO of Syngene International.

Expect good momentum to continue in H2FY18: Syngene CEO

From a revenue point of view, they have now surpassed the level they were at pre-fire. However, on the operational side the building is still out of action, said Jonathan Hunt, CEO of Syngene.

Aurobindo's Hyd unit getting form 483 a non-event: Surajit Pal

USFDA has issued notice to the Hyderabad unit of Aurobindo Pharma and calming the nerves of the investors Surajit Pal of Prabhudas Lilladher says that it is a non-event and there is no need to worry.

Demonetisation has impacted Indian sales, not exports: Biocon

Speaking to CNBC-TV18, Kiran Mazumdar Shaw, CMD of Biocon said huge opportunities exist for Biocon in the US biosimilars market.

Will scale up contract mfg; $200 mn capex for key arms: Syngene

Of USD 200 million capex, USD 100 million will go into four key areas- Syngene Research Centre, biologic centre, formulation center, viral testing and the rest in commercial manufacturing, says Jonathan Hunt, CEO of Syngene International.

Hedging protects co from currency volatility: Syngene's COO

Manoj Nerurkar, COO, Syngene, says he expects the company to grow in line with its second quarter results.

Will focus on capacity expansion, customer needs: Syngene

Peter Bains, Director & CEO of Syngene told CNBC-TV18 growing client base and expanding capacity will aid growth in future.

Eye 20% CAGR growth in future; expansion plans on: Syngene

In an interview with CNBC-TV18, Peter Bains, CEO of Syngene International says that the company will invest nearly USD 100 million for a new plant in Mangalore, which will become functional in 2018.